BORDEAUX, France–(BUSINESS WIRE)–Regulatory news:
Aelis Farma (ISIN code: FR0014007ZB4 – mnemonic: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases (the “ Company “), announces today that its annual financial report for the financial year ended December 31, 2021 has been made available to the public and filed with the Autorité des marchés financiers (Financial Markets Authority).
The Company’s annual financial report includes:
– the management report;
– the report on corporate governance;
– the annual accounts;
– the reports of the statutory auditors.
It can be viewed on the Company’s website at www.aelisfarma.com.
About AELIS FARMA
Founded in 2013, Aelis Farma is a biopharmaceutical company developing a new class of drugs, specific inhibitors of CB1 receptor signaling of the endocannabinoid system (CB1-SSi). These new molecules have great potential in the treatment of many brain diseases. CB1-SSi were developed by Aelis Farma based on the discovery of a new natural brain defense mechanism made by the team of Dr. Pier Vincenzo Piazza, CEO of the Company, when he was director of the Neurocentre Inserm Magendie in Bordeaux. For these discoveries, Dr. Piazza received the Inserm Grand Prix and the French Academy of Sciences Grand Prix of Neurology, which are among the most prestigious French awards in medicine and neurology.
Aelis Farma is developing two first-in-class drug candidates that are at the clinical stage, AEF0117 and AEF0217, and has a portfolio of innovative CB1-SSi for the treatment of other diseases associated with dysregulation of CB1 receptor activity .
AEF0117, which targets disorders due to excessive cannabis use (addiction and psychosis), has demonstrated efficacy in a phase 2a clinical trial and will enter a phase 2b clinical trial in the United States in 2022. Aelis Farma has an agreement exclusive optional license agreement with Indivior PLC, a leading addiction treatment pharmaceutical company, for the development and commercialization of AEF0117 for cannabis abuse disorders. As part of this agreement, Aelis Farma received 30 million dollars (option payment). If Indivior exercises the license option at the end of phase 2b, Aelis Farma will receive a $100 million royalty (potentially in 2024) and up to $340 million in additional payments depending on the achievement of development, regulatory and commercial milestones, as well as royalties on net sales of AEF0117 of between 12% and 20%.
AEF0217, which targets various cognitive disorders including those associated with trisomy 21, is successfully progressing its phase 1/2 program and could provide the first evidence of efficacy in early 2023. This compound has been the subject of an extensive program of preclinical proof of concept using highly innovative and highly predictive tests to assess cognitive functions. In this context, AEF0217 has demonstrated the ability to completely reverse deficits in several models of cognitive disorders such as Down syndrome and fragile X syndrome, as well as in models of certain cognitive deficits associated with aging.
Based in Bordeaux, within the Neurocentre Inserm Magendie, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui -invest and IRDI Capital Investissement.
For more information: www.aelisfarma.com
ISIN Code: FR0014007ZB4
Compartment B of Euronext Paris